Home Blog of Signal Transduction Transmembrane Transporters SGLT

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

SGLT

Phase II drugs under clinical investigation for the treatment of chronic constipation

144 views | Sep 10 2023

New investigational drugs for the treatment of chronic constipation show promise in terms of improved effectiveness and tolerability, but further clinical trials with larger sample sizes and longer durations are needed to establish their efficacy and safety. [Read the Full Post]

Phloretin Improves Ultrafiltration and Reduces Glucose Absorption during Peritoneal Dialysis in Rats

66 views | Sep 10 2023

The study found that blocking facilitative glucose channels with phloretin reduced glucose absorption and improved ultrafiltration efficiency in peritoneal dialysis, suggesting it as a promising approach for therapeutic interventions in this context. [Read the Full Post]

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease

102 views | Jul 18 2023

The study found that sotagliflozin, at a dose of 400 mg but not 200 mg, significantly reduced HbA1c levels compared to placebo after 26 weeks in adults with type 2 diabetes and stage 3 chronic kidney disease, while both doses showed reductions in urine albumin-creatinine ratio at week 26, but not sustained at week 52, and the safety profile was similar to previous reports. [Read the Full Post]

Mortality trends of aortic stenosis in high-income countries from 2000 to 2020

91 views | Jul 18 2023

This study investigates recent mortality trends from aortic stenosis among eight high-income countries, revealing an increase in crude mortality rates but shifts towards decreasing trends in age-standardized rates in three countries and among individuals aged ≥80 years. [Read the Full Post]

Empagliflozin and sacubitril/valsartan reverse methotrexate cardiotoxicity by repressing oxidative stress and hypoxia in heart embryonic H9c2 cardiomyocytes - the role of morphology of mitochondria observed on electron microscopy

119 views | Jul 12 2023

S/V and EMPA treatment demonstrated significant reductions in HIF-1α levels and oxidative stress markers, along with increased antioxidant parameters and improved mitochondria morphology in H9c2 rat embryonic cardiomyocyte cells. [Read the Full Post]

Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial

70 views | May 04 2023

The post hoc analysis of the VERTIS CV trial found that the beneficial effects of ertugliflozin on kidney outcomes were not affected by baseline heart failure status in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. [Read the Full Post]

The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review

100 views | Apr 04 2023

SGLT2 inhibitors have shown a beneficial effect in reducing cardiovascular mortality and morbidity in patients with type 2 diabetes mellitus and may have a broader application beyond diabetes. [Read the Full Post]

Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor

58 views | Feb 25 2023

Our study found that high glucose conditions in kidney cells altered the metabolomic profile, and treatment with SGLT2 inhibitor dapagliflozin led to significant changes in the levels of metabolites such as asparagine, PC ae C34:1 and PC ae C36:2 in tubular epithelial cells, and PC aa C32:0 in podocytes, which affected multiple metabolic pathways. [Read the Full Post]

Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation

86 views | Feb 25 2023

Dapagliflozin, a SGLT2 inhibitor, improves cardiac function in doxorubicin-induced dilated cardiomyopathy by suppressing the activation of the NLRP3 inflammasome through decreased p38-dependent TLR4 expression. [Read the Full Post]

Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study

84 views | Oct 28 2022

Lorena Pérez-Carrillo et al. showed alterations in several sodium transports and reinforced the importance of channels in HF progression. [Read the Full Post]